Overview

Inhaled NAC in Treatment of IPF

Status:
Withdrawn

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Colorado, Denver

Treatments:

Acetylcysteine
N-monoacetylcystine